HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/